|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2015-02-13 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2012-07-23 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2010-11-15 |
AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study
After progression of disease after one chemotherapy, metastatic breast cancer patients will be randomized 1:1 to one of the following treatment arms:
Arm A. Eribulin Arm B. Paclitaxel
Blood draws for immune analysis will be performed before start of therapy, on day 1 of cycle 2 and on day 21 of cycle 4 (end of therapy) for the primary study aim. Patients will be treated under study conditions for a maximum of 4 therapy cycles.
PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa®) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures
The primary purpose of this study is to investigate the effectiveness reflected by the retention rate of perampanel as the only add-on treatment in adult participants with primary generalized tonic-clonic (PGTC) or secondarily generalized tonic-clonic (SGTC) seizures based on focal or idiopathic generalized epilepsy in a non-interventional (observational) setting.
IMMUNIB - An Open-label, Single-arm Phase II Study of Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular
This is an exploratory, open-label, single arm, multicenter phase II trial for the evaluation of efficacy and feasibility (as determined by safety and tolerability) of immunotherapy with nivolumab in combination with lenvatinib for patients with multinodular, advanced stage hepatocellular carcinoma in first line therapy
100 项与 Eisai GmbH 相关的临床结果
0 项与 Eisai GmbH 相关的专利(医药)
100 项与 Eisai GmbH 相关的药物交易
100 项与 Eisai GmbH 相关的转化医学